Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cellline mouse models

Yukihiko Hiroshima, Yong Zhang, Takashi Murakami, Ali Maawy, Shinji Miwa, Mako Yamamoto, Shuuya Yano, Sho Sato, Masashi Momiyama, Ryutaro Mori, Ryusei Matsuyama, Takashi Chishima, Kuniya Tanaka, Yasushi Ichikawa, Michael Bouvet, Itaru Endo, Ming Zhao, Robert M. Hoffman

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

The aim of the present study was to examine the efficacy of tumor-targeting Salmonella typhimurium A1-R treatment following anti-vascular endothelial growth factor (VEGF) therapy on VEGF-positive human pancreatic cancer. A pancreatic cancer patient-derived orthotopic xenograft (PDOX) that was VEGF-positive and an orthotopic VEGF-positive human pancreatic cancer cell line (MiaPaCa-2-GFP) as well as a VEGFnegative cell line (Panc-1) were tested. Nude mice with these tumors were treated with gemcitabine (GEM), bevacizumab (BEV), and S. typhimurium A1-R. BEV/GEM followed by S. typhimurium A1-R significantly reduced tumor weight compared to BEV/GEM treatment alone in the PDOX and MiaPaCa-2 models. Neither treatment was as effective in the VEGF-negative model as in the VEGF-positive models. These results demonstrate that S. typhimurium A1-R following anti-angiogenic therapy is effective on pancreatic cancer including the PDOX model, suggesting its clinical potential.

Original languageEnglish
Pages (from-to)12346-12357
Number of pages12
JournalOncotarget
Volume5
Issue number23
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

gemcitabine
Salmonella typhimurium
Pancreatic Neoplasms
Heterografts
Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Cell Line
Tumor Burden
Nude Mice
Bevacizumab

Keywords

  • Anti-angiogenic therapy
  • Bevacizumab
  • Gemcitabine
  • GFP
  • Nude mice
  • Orthotopic
  • Pancreatic cancer
  • Patient-derived orthotopic xenograft (PDOX)
  • Salmonella typhimurium A1-R
  • VEGF

ASJC Scopus subject areas

  • Oncology

Cite this

Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cellline mouse models. / Hiroshima, Yukihiko; Zhang, Yong; Murakami, Takashi; Maawy, Ali; Miwa, Shinji; Yamamoto, Mako; Yano, Shuuya; Sato, Sho; Momiyama, Masashi; Mori, Ryutaro; Matsuyama, Ryusei; Chishima, Takashi; Tanaka, Kuniya; Ichikawa, Yasushi; Bouvet, Michael; Endo, Itaru; Zhao, Ming; Hoffman, Robert M.

In: Oncotarget, Vol. 5, No. 23, 01.01.2014, p. 12346-12357.

Research output: Contribution to journalArticle

Hiroshima, Y, Zhang, Y, Murakami, T, Maawy, A, Miwa, S, Yamamoto, M, Yano, S, Sato, S, Momiyama, M, Mori, R, Matsuyama, R, Chishima, T, Tanaka, K, Ichikawa, Y, Bouvet, M, Endo, I, Zhao, M & Hoffman, RM 2014, 'Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cellline mouse models', Oncotarget, vol. 5, no. 23, pp. 12346-12357. https://doi.org/10.18632/oncotarget.2641
Hiroshima, Yukihiko ; Zhang, Yong ; Murakami, Takashi ; Maawy, Ali ; Miwa, Shinji ; Yamamoto, Mako ; Yano, Shuuya ; Sato, Sho ; Momiyama, Masashi ; Mori, Ryutaro ; Matsuyama, Ryusei ; Chishima, Takashi ; Tanaka, Kuniya ; Ichikawa, Yasushi ; Bouvet, Michael ; Endo, Itaru ; Zhao, Ming ; Hoffman, Robert M. / Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cellline mouse models. In: Oncotarget. 2014 ; Vol. 5, No. 23. pp. 12346-12357.
@article{3c191d8fb648402585134ed8b73e6969,
title = "Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cellline mouse models",
abstract = "The aim of the present study was to examine the efficacy of tumor-targeting Salmonella typhimurium A1-R treatment following anti-vascular endothelial growth factor (VEGF) therapy on VEGF-positive human pancreatic cancer. A pancreatic cancer patient-derived orthotopic xenograft (PDOX) that was VEGF-positive and an orthotopic VEGF-positive human pancreatic cancer cell line (MiaPaCa-2-GFP) as well as a VEGFnegative cell line (Panc-1) were tested. Nude mice with these tumors were treated with gemcitabine (GEM), bevacizumab (BEV), and S. typhimurium A1-R. BEV/GEM followed by S. typhimurium A1-R significantly reduced tumor weight compared to BEV/GEM treatment alone in the PDOX and MiaPaCa-2 models. Neither treatment was as effective in the VEGF-negative model as in the VEGF-positive models. These results demonstrate that S. typhimurium A1-R following anti-angiogenic therapy is effective on pancreatic cancer including the PDOX model, suggesting its clinical potential.",
keywords = "Anti-angiogenic therapy, Bevacizumab, Gemcitabine, GFP, Nude mice, Orthotopic, Pancreatic cancer, Patient-derived orthotopic xenograft (PDOX), Salmonella typhimurium A1-R, VEGF",
author = "Yukihiko Hiroshima and Yong Zhang and Takashi Murakami and Ali Maawy and Shinji Miwa and Mako Yamamoto and Shuuya Yano and Sho Sato and Masashi Momiyama and Ryutaro Mori and Ryusei Matsuyama and Takashi Chishima and Kuniya Tanaka and Yasushi Ichikawa and Michael Bouvet and Itaru Endo and Ming Zhao and Hoffman, {Robert M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2641",
language = "English",
volume = "5",
pages = "12346--12357",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "23",

}

TY - JOUR

T1 - Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cellline mouse models

AU - Hiroshima, Yukihiko

AU - Zhang, Yong

AU - Murakami, Takashi

AU - Maawy, Ali

AU - Miwa, Shinji

AU - Yamamoto, Mako

AU - Yano, Shuuya

AU - Sato, Sho

AU - Momiyama, Masashi

AU - Mori, Ryutaro

AU - Matsuyama, Ryusei

AU - Chishima, Takashi

AU - Tanaka, Kuniya

AU - Ichikawa, Yasushi

AU - Bouvet, Michael

AU - Endo, Itaru

AU - Zhao, Ming

AU - Hoffman, Robert M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The aim of the present study was to examine the efficacy of tumor-targeting Salmonella typhimurium A1-R treatment following anti-vascular endothelial growth factor (VEGF) therapy on VEGF-positive human pancreatic cancer. A pancreatic cancer patient-derived orthotopic xenograft (PDOX) that was VEGF-positive and an orthotopic VEGF-positive human pancreatic cancer cell line (MiaPaCa-2-GFP) as well as a VEGFnegative cell line (Panc-1) were tested. Nude mice with these tumors were treated with gemcitabine (GEM), bevacizumab (BEV), and S. typhimurium A1-R. BEV/GEM followed by S. typhimurium A1-R significantly reduced tumor weight compared to BEV/GEM treatment alone in the PDOX and MiaPaCa-2 models. Neither treatment was as effective in the VEGF-negative model as in the VEGF-positive models. These results demonstrate that S. typhimurium A1-R following anti-angiogenic therapy is effective on pancreatic cancer including the PDOX model, suggesting its clinical potential.

AB - The aim of the present study was to examine the efficacy of tumor-targeting Salmonella typhimurium A1-R treatment following anti-vascular endothelial growth factor (VEGF) therapy on VEGF-positive human pancreatic cancer. A pancreatic cancer patient-derived orthotopic xenograft (PDOX) that was VEGF-positive and an orthotopic VEGF-positive human pancreatic cancer cell line (MiaPaCa-2-GFP) as well as a VEGFnegative cell line (Panc-1) were tested. Nude mice with these tumors were treated with gemcitabine (GEM), bevacizumab (BEV), and S. typhimurium A1-R. BEV/GEM followed by S. typhimurium A1-R significantly reduced tumor weight compared to BEV/GEM treatment alone in the PDOX and MiaPaCa-2 models. Neither treatment was as effective in the VEGF-negative model as in the VEGF-positive models. These results demonstrate that S. typhimurium A1-R following anti-angiogenic therapy is effective on pancreatic cancer including the PDOX model, suggesting its clinical potential.

KW - Anti-angiogenic therapy

KW - Bevacizumab

KW - Gemcitabine

KW - GFP

KW - Nude mice

KW - Orthotopic

KW - Pancreatic cancer

KW - Patient-derived orthotopic xenograft (PDOX)

KW - Salmonella typhimurium A1-R

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84920031401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920031401&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2641

DO - 10.18632/oncotarget.2641

M3 - Article

C2 - 25402324

AN - SCOPUS:84920031401

VL - 5

SP - 12346

EP - 12357

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -